Collplant Biotechnologies (NASDAQ: CLGN) — Perfil da empresa, notícias e dados financeiros
Collplant Biotechnologies uses plant-based rhCollagen technology for regenerative medicine and tissue repair products.

Collplant Biotechnologies
Collplant Biotechnologies (NASDAQ:CLGN) specializes in regenerative and aesthetic medicine by leveraging its proprietary plant-based rhCollagen technology. This innovative approach aims at developing tissue repair products, bioinks for 3D bioprinting, and dermal fillers. Their groundbreaking projects include research into life-saving organs and skin regeneration treatments. The company's goal is to revolutionize medical treatments and improve patient outcomes through sustainable, scalable, and high-purity collagen production. Collplant is committed to expanding its portfolio of regenerative medicine products while focusing on strategic partnerships and technological advancements to meet the growing global demand.
Resumo
Operações
Produtos e/ou serviços de Collplant Biotechnologies
- Development and commercialization of rhCollagen-based regenerative medical products for tissue repair and organ manufacturing.
- Production of bioprinted tissues and organs utilizing proprietary recombinant human collagen (rhCollagen) technology.
- Creation of VergenixSTR, an injectable gel for the treatment of tendinitis.
- Development of VergenixFG, a flowable gel wound filler designed for the management of chronic wounds.
- Innovation in aesthetic medicine through rhCollagen-based dermal fillers for cosmetic procedures.
- Collaboration on research projects to explore the use of rhCollagen in various biomedical applications.
equipe executiva do Collplant Biotechnologies
- Yehiel TalCEO & Chairman
- Eran RotemDeputy CEO & CFO
- Oren FahimipoorVice President of Operations
- Oded ShoseyovFounder & Chief Scientist
- Bar AbelisVice President of Legal
- Hadas Dreiher HorowitzVice President of Human Resources
Últimas notícias sobre a Collplant Biotechnologies
CollPlant completes LightSolver acquisition
United StatesCollPlant to acquire LightSolver photonic computing technology
United StatesCollPlant explores strategic options as revenue drops following milestone loss
United StatesCollPlant narrowed net loss in 2025 as AbbVie milestone drives revenue surge
United States
Principais indicadores financeiros
Resultados divulgados pela Collplant Biotechnologies, em USD.
- Cap. de mercado
- 11,4 mi
- Receita (TTM)
- 318 mil
- P/L
- —
- LPA (diluído, TTM)
- -9.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 2,4 mi | -11,5 mi | -11,5 mi | |
| 515 mil | -17,3 mi | -16,6 mi | |
| 11 mi | -7,5 mi | -7 mi | |
| 299 mil | -17,1 mi | -16,9 mi |